BioMarin
BioMarin, founded in 1997, markets eight products treating life-threatening conditions and operates in over 70 countries with more than 3,000 employees globally.
Company History
BioMarin was founded in 1997. Since its inception, the company has focused on developing and marketing innovative therapies for life-threatening conditions. Over the years, BioMarin has grown significantly and now operates in over 70 countries. The company employs more than 3,000 people globally, emphasizing its commitment to improving patient outcomes through its specialized products.
Products
BioMarin markets eight products that target a range of severe and life-threatening conditions. These include therapies for achondroplasia, severe hemophilia A, and several rare inherited and lysosomal storage diseases. Each product aims to offer critical support and treatment options for patients suffering from these challenging health issues.
Global Operations
BioMarin operates across more than 70 countries, showcasing its extensive global reach. The company employs over 3,000 people worldwide, supporting numerous therapeutic areas and ensuring that their products are accessible to patients on an international scale.
Manufacturing Facilities
BioMarin has manufacturing facilities located in Novato, California, and Shanbally, Ireland. These sites are instrumental in producing the complex therapies that patients rely on. The facilities adhere to stringent standards, being certified to ISO 14001 Environmental Management Systems and ISO 45001 Occupational Health and Safety Management Systems.
Research and Development
BioMarin is advancing an industry-leading pipeline of investigational medicines. These are in various stages of clinical and preclinical development. The company's R&D efforts are focused on developing new therapies that could potentially address unmet medical needs and improve the quality of life for patients with severe diseases.